Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Leiomyosarcoma is a type of cancer that forms in smooth muscle. Researchers want to see if adding ADI-PEG 20 to the usual chemotherapy for leiomyosarcoma works better than chemotherapy alone. The people in this study have leiomyosarcoma that keeps growing despite treatment.
The purpose of this study is to find the highest dose of the investigational drug BCA101 that can be given safely alone and in combination with the immunotherapy drug pembrolizumab in patients with advanced lung cancer that cannot be cured with standard treatments. BCA101 is an antibody that targets two proteins involved in cancer growth called EGFR and TGF-beta. By blocking these proteins, BCA101 may interfere with the signals that spur cancer growth. 
Researchers want to find the best dose of DCC-3116 to give with ripretinib for people with gastrointestinal stromal tumor (GIST). The people in this study have GIST that has spread, even with treatment.
The purpose of this study is to find the highest dose of the investigational drug RMC-6236 that can be given safely in people with advanced solid tumors containing mutations in the KRAS gene. RMC-6236 targets the KRAS protein made by the mutated gene. The KRAS protein sends signals that cause cancer cells to grow. RMC-6236 is designed to prevent the KRAS protein from sending these signals, and this blocking action may slow or stop the growth of cancer cells. RMC-6236 is taken orally (by mouth).
In this study, researchers want to see how safe IDRX-42 is and how well it works to treat cancer. The people in this study have gastrointestinal stromal tumor (GIST) that keeps growing after treatment. In addition, their cancer has metastasized (spread) or is inoperable (cannot be taken out with surgery).
Researchers want to find the best dose of ABBV-453 to treat multiple myeloma. The people in this study have multiple myeloma that may have a genetic change and make too much of the BCL2 protein. In addition, their cancer has not responded to treatment or has returned after treatment.
Researchers are seeking the best dose of safusidenib erbumine to treat glioma that came back or keeps growing after treatment. The people in this study have glioma with a mutation (change or variant) in a gene called IDH1. Many gliomas have IDH1 mutations, which help cancer cells survive and grow.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are assessing the combination of sacituzumab govitecan and cetuximab for treating head and neck cancer. The people in this study have squamous cell cancer of the head and neck. Their cancer came back or spread after prior treatment.
The purpose of this study is to find the best dose of the drug selinexor that can be given safely with radiation therapy in young patients newly diagnosed with pediatric diffuse intrinsic pontine glioma (DIPG) or high-grade glioma. Researchers will also determine the effectiveness of combining selinexor with radiation therapy (given for eight weeks) followed by selinexor therapy alone for two years.
